Metoprolol Succinate
Product Images NDC 71610-509

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 71610-509). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 100 mg (71610 0509 45)

Bottle Label 100 mg (71610 0509 45)
METOPROLOL SUCCINATE ER 100 mg tablet bottle label showing 45 count. The label includes NDC number 71610-0509-45 and storage instructions. Labeler is Aphena Pharma Solutions - Tennessee, LLC, with manufacturer AstraZeneca AB, Sodertalje, Sweden. The label states prescription use only and provides lot number, serial number, batch number, and expiration date.*
FDA Label Image

Bottle Label 25 mg (71610 0512 45)

Bottle Label 25 mg (71610 0512 45)
Label for METOPROLOL SUCCINATE ER 25 mg tablets, bottle containing 45 tablets. Manufactured by AstraZeneca AB and repackaged by Aphena Pharma Solutions in Cookeville, Tennessee 38501. The label includes storage instructions, barcode, lot number, and expiration date.*
FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Structuralformula (Image 01)

Structuralformula (Image 01)
Chemical structure of metoprolol succinate, showing the metoprolol moiety and the succinate part in the molecule.*
FDA Label Image

Merit Graphic (Image 02)

Merit Graphic (Image 02)
A forest plot chart titled "Results for Subgroups in MERIT-HF" displaying relative risk and 95% confidence intervals for metoprolol succinate extended release tablets versus placebo across various subgroups. The chart includes three panels comparing total mortality, total mortality or all-cause hospitalization, and total mortality or hospitalization for heart failure, with subgroups listed by demographics and clinical factors such as region, NYHA class, ejection fraction, etiology, sex, race, previous myocardial infarction, diabetes, hypertension, and heart rate.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.